Exelixis (EXEL)
(Delayed Data from NSDQ)
$26.97 USD
-0.20 (-0.74%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $26.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.97 USD
-0.20 (-0.74%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $26.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Novo Nordisk Confirms Bid for Ablynx But Faces Rejection
by Zacks Equity Research
Novo Nordisk (NVO) confirmed its revised offer made on Dec 22, to acquire Ablynx NV for $3.1 billion.
Agenus Inc., (AGEN) Jumps: Stock Rises 11.4%
by Zacks Equity Research
Agenus Inc. (AGEN) was a big mover last session, as the company saw its shares more than 11% on the day amid huge volumes.
Alnylam, Sanofi Announce Restructuring Deal for RNAi Products
by Zacks Equity Research
Alnylam (ALNY) and Sanofi entered into a strategic restructuring of their RNAi therapeutics rare genetic diseases alliance.
The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines
Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced an amendment to the protocol for the phase Ib trial of cabozantinib combined with Tecentriq whereby there will be four new expansion cohorts to the trial.
Cancer Space Update: New Regulatory Status for 3 Major Drugs
by Zacks Equity Research
Merck's Keytruda receives approval in Japan for bladder cancer. Seattle Genetics' Adcetris and Novartis' Kisqali get regulatory status updates from the FDA.
Emergent Starts Phase II Study on Anti-influenza Candidate
by Zacks Equity Research
Emergent (EBS) initiates a phase II dose-ranging trial to evaluate the safety, pharmacokinetics and clinical benefit of its investigational FLU-IGIV to treat influenza virus infection.
United Therapeutics (UTHR) Collaborates With Corsair Pharma
by Zacks Equity Research
United Therapeutics (UTHR) entered into an exclusive license agreement with Corsair Pharma.
Pfizer (PFE) Collaborates With Sangamo for Gene Therapy
by Zacks Equity Research
Pfizer entered into collaboration agreements with Sangamo Therapeutics and private biotech, Arvinas.
Inovio Amends Chinese Deal for Immunotherapy, Shares Up
by Zacks Equity Research
Inovio (INO) entered into an amended agreement with ApolloBio Corporation and grants ApolloBio the exclusive right to develop and commercialize VGX-3100 within Greater China.
Valeant (VRX) to Settle Allergan Litigation for $290 Million
by Zacks Equity Research
Valeant (VRX) and Pershing Square decided to resolve the claims of the long standing Allergan lawsuit for $290 million. Valeant will now pay 33% of the costs, down from the previous agreement of 60%.
Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?
by Zacks Equity Research
Exelixis (EXEL) had a phenomenal run in 2017 driven by sales of Cabometyx and we expect the momentum to continue in 2018 on the back of the label expansion of the drug.
Exelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer
by Zacks Equity Research
Exelixis (EXEL) received a significant boost with the approval of label expansion of lead drug Cabometyx for first-line kidney cancer.
Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak
by Zacks Equity Research
Endo (ENDP) announced better-than-expected results for the third quarter. However, weakness in the generics segment persist and will impact results.
Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up
by Zacks Equity Research
Perrigo (PRGO) posts better-than-expected earnings with revenues also beating estimates. The company ups its guidance, courtesy of a continued positive execution across all business segments.
Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up
by Zacks Equity Research
Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates
by Zacks Equity Research
Pacira's (PCRX) earnings surpassed estimates but sales missed the same in the third quarter of 2017. The company remains focused on the label expansion of Exparel.
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Catalyst Pharma (CPRX) remains focused on the development of its pipeline candidate firdapse in the third quarter of 2017.
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down
by Zacks Equity Research
VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.
Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Increased operating expenses mar Aerie's (AERI) Q3 performance.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) earnings beat estimates while revenues miss the same in Q3. The company also cuts its guidance due to lower-than-expected sales from Xyrem.
Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up
by Zacks Equity Research
Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.
Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag
by Zacks Equity Research
Agenus (AGEN) incurred in line loss but sales missed estimates in the third quarter of 2017.
Infinity (INFI) Q3 Loss Narrower than Expected, View Intact
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) Q3 loss was narrower than estimates and the year-ago quarter loss.
AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda
by Zacks Equity Research
AVEO Pharmaceuticals reported narrower-than-expected adjusted loss in the third quarter. Moreover, it received approval for its first drug, Fotivda, which was approved in EU for bladder cancer.